癌症疫苗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "癌症疫苗" in Chinese language version.

refsWebsite

Global rank Chinese rank

8web.archive.org

1^st place

7nih.gov

4^th place

5^th place

6doi.org

2^nd place

23^rd place

2worldcat.org

5^th place

12^th place

1jofs.in

low place

1vaccinenewsdaily.com

low place

1nature.com

234^th place

227^th place

1amgen.com

low place

1asco.org

low place

1fda.gov

447^th place

581^st place

1genengnews.com

low place

1the-scientist.com

7,827^th place

5,345^th place

1sciencedirect.com

149^th place

292^nd place

amgen.com

Amgen press release. Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma. Mar 19, 2013. Available here （页面存档备份，存于互联网档案馆）

asco.org

Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. （页面存档备份，存于互联网档案馆） S. J. Schuster, et al. 2009 ASCO Annual Meeting, J Clin Oncol 27:18s, 2009 (suppl; abstr 2)

doi.org

dx.doi.org

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.. Nature. 2001-04-26, 410 (6832): 1107–1111. PMID 11323675. doi:10.1038/35074122.
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22 (i): 329–60. PMID 15032581. doi:10.1146/annurev.immunol.22.012703.104803.
Pejawar-Gaddy S, Finn O. Cancer vaccines: Accomplishments and challenges. Critical Reviews in Oncology Hematology. 2008, 67: 93–102. doi:10.1016/j.critrevonc.2008.02.010.
Nishikawa, Makiya; Takemoto, Seiji; Takakura, Yoshinobu. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. International Journal of Pharmaceutics. Special Issue in Honor of Prof. Tsuneji Nagai. 2008-04-16, 354 (1–2): 23–27. doi:10.1016/j.ijpharm.2007.09.030.
Savvateeva, L. V.; Schwartz, A. M.; Gorshkova, L. B.; Gorokhovets, N. V.; Makarov, V. A.; Reddy, V. P.; Aliev, G.; Zamyatnin, A. A. Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice. Current Molecular Medicine. 2015-01-01, 15 (5): 462–468 [2018-05-27]. ISSN 1875-5666. PMID 26122656. doi:10.2174/1566524015666150630125024. （原始内容存档于2019-06-05）.
Johnson, Robert S.; Walker, Anthony I.; Ward, Stephen J. Cancer vaccines: will we ever learn?. Expert Review of Anticancer Therapy. 2009-01-01, 9 (1): 67–74. ISSN 1473-7140. doi:10.1586/14737140.9.1.67.

fda.gov

Approval Letter - Provenge. Food and Drug Administration. 2010-04-29 [2018-05-27]. （原始内容存档于2017-07-23）.

genengnews.com

What Comes After Dendreon's Provenge?. 18 Oct 2010 [2018-05-27]. （原始内容存档于2016-08-14）.

jofs.in

Arvind Babu RS; Kiran Kumar K; Sridhar Reddy G; Anuradha Ch. Cancer Vaccine : A Review (PDF). Journal of Orofacial Sciences. 2010, 2 (3): 77–82 [2018-05-27]. （原始内容 (PDF)存档于2018-05-27）.

nature.com

Ralph M. Steinman1 and Jacques Banchereau. "Taking dendritic cells into medicine. " Nature 449, 419-426, 27 September 2007 * nature06175 （页面存档备份，存于互联网档案馆）

nih.gov

ncbi.nlm.nih.gov

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.. Nature. 2001-04-26, 410 (6832): 1107–1111. PMID 11323675. doi:10.1038/35074122.
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22 (i): 329–60. PMID 15032581. doi:10.1146/annurev.immunol.22.012703.104803.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. (2001 Apr 26). "IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.". Nature 410(6832): 1107–1111. PMID 11323675.
Dunn GP, Old LJ, Schreiber RD. (2004). "The three Es of cancer immunoediting.". Annual Rev Immunology 22: 329-360. PMID 15032581.
Giarelli E (2007). "Cancer vaccines: a new frontier in prevention and treatment". Oncology (Williston Park) 21 (11 Suppl Nurse Ed): 11–8. PMID 18154203.
Giarelli E. Cancer vaccines: a new frontier in prevention and treatment. Oncology (Williston Park). 2007, 21 (11 Suppl Nurse Ed): 11–8. PMID 18154203.
Savvateeva, L. V.; Schwartz, A. M.; Gorshkova, L. B.; Gorokhovets, N. V.; Makarov, V. A.; Reddy, V. P.; Aliev, G.; Zamyatnin, A. A. Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice. Current Molecular Medicine. 2015-01-01, 15 (5): 462–468 [2018-05-27]. ISSN 1875-5666. PMID 26122656. doi:10.2174/1566524015666150630125024. （原始内容存档于2019-06-05）.

sciencedirect.com

Nishikawa, Makiya; Takemoto, Seiji; Takakura, Yoshinobu. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. International Journal of Pharmaceutics. Special Issue in Honor of Prof. Tsuneji Nagai. 2008-04-16, 354 (1–2): 23–27. doi:10.1016/j.ijpharm.2007.09.030.

the-scientist.com

Dead. ^{[失效連結]}

vaccinenewsdaily.com

Oral vaccine could fight source of stomach cancers. Vaccine News Reports. [2018-05-27]. （原始内容存档于2015-04-24）.

web.archive.org

Arvind Babu RS; Kiran Kumar K; Sridhar Reddy G; Anuradha Ch. Cancer Vaccine : A Review (PDF). Journal of Orofacial Sciences. 2010, 2 (3): 77–82 [2018-05-27]. （原始内容 (PDF)存档于2018-05-27）.
Oral vaccine could fight source of stomach cancers. Vaccine News Reports. [2018-05-27]. （原始内容存档于2015-04-24）.
Ralph M. Steinman1 and Jacques Banchereau. "Taking dendritic cells into medicine. " Nature 449, 419-426, 27 September 2007 * nature06175 （页面存档备份，存于互联网档案馆）
Amgen press release. Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma. Mar 19, 2013. Available here （页面存档备份，存于互联网档案馆）
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. （页面存档备份，存于互联网档案馆） S. J. Schuster, et al. 2009 ASCO Annual Meeting, J Clin Oncol 27:18s, 2009 (suppl; abstr 2)
Approval Letter - Provenge. Food and Drug Administration. 2010-04-29 [2018-05-27]. （原始内容存档于2017-07-23）.
What Comes After Dendreon's Provenge?. 18 Oct 2010 [2018-05-27]. （原始内容存档于2016-08-14）.
Savvateeva, L. V.; Schwartz, A. M.; Gorshkova, L. B.; Gorokhovets, N. V.; Makarov, V. A.; Reddy, V. P.; Aliev, G.; Zamyatnin, A. A. Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice. Current Molecular Medicine. 2015-01-01, 15 (5): 462–468 [2018-05-27]. ISSN 1875-5666. PMID 26122656. doi:10.2174/1566524015666150630125024. （原始内容存档于2019-06-05）.

worldcat.org

Savvateeva, L. V.; Schwartz, A. M.; Gorshkova, L. B.; Gorokhovets, N. V.; Makarov, V. A.; Reddy, V. P.; Aliev, G.; Zamyatnin, A. A. Prophylactic Admission of an In Vitro Reconstructed Complexes of Human Recombinant Heat Shock Proteins and Melanoma Antigenic Peptides Activates Anti-Melanoma Responses in Mice. Current Molecular Medicine. 2015-01-01, 15 (5): 462–468 [2018-05-27]. ISSN 1875-5666. PMID 26122656. doi:10.2174/1566524015666150630125024. （原始内容存档于2019-06-05）.
Johnson, Robert S.; Walker, Anthony I.; Ward, Stephen J. Cancer vaccines: will we ever learn?. Expert Review of Anticancer Therapy. 2009-01-01, 9 (1): 67–74. ISSN 1473-7140. doi:10.1586/14737140.9.1.67.